Search

Your search keyword '"Bloch, Orin"' showing total 308 results
Start Over Author "Bloch, Orin" Language english
308 results on '"Bloch, Orin"'

18. A Feasibility Study on a Portable Vision Device for Patients with Stroke and Brain Tumours.

Author

Nisanova, Arina, Barrios, Laurel, Chokshi, Tanvi, Mannis, Mark, Bloch, Orin, and Liu, Yin Allison

Subjects
BRAIN tumors, PATIENTS' attitudes, LOW vision, VISUAL acuity, STROKE patients, PERIMETRY
Abstract

This prospective, single-centre cohort study aimed to evaluate the impact of a portable vision reading device, OrCam Read, on vision-related quality-of-life and independent functional status in patients with low vision due to stroke or brain tumours. Six patients with poor visual acuity or visual field defects due to a stroke or a brain tumour were enrolled at a U.S. Ophthalmology Department. Participants were trained to use OrCam Read and given a loaner device for the 1 month duration of the study. Various assessments, including daily function tests, the National Eye Institute Visual Function Questionnaire-25, and the 10-item neuro-ophthalmic supplement, were administered at the first and last visits. Patients' experience with the device was evaluated with weekly telephone and end-of-study satisfaction surveys. The main outcome measures were the patient satisfaction with OrCam and the mean assessment scores between enrolment and final visits. The intervention with OrCam significantly improved patients' ability to complete daily tasks and participants reported good satisfaction with the device. The results also show non-significant improvement with distant activities, dependency, and role difficulties. Our findings demonstrate the feasibility of studying vision-related quality-of-life using a portable vision device in this patient population and pave the way for a larger study to validate the results of this study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment.

Author

Aboud, Orwa, Liu, Yin, Dahabiyeh, Lina, Abuaisheh, Ahmad, Li, Fangzhou, Aboubechara, John Paul, Riess, Jonathan, Bloch, Orin, Hodeify, Rawad, Tagkopoulos, Ilias, and Fiehn, Oliver

Subjects
BIOGENIC amines, GLIOBLASTOMA multiforme, ISOCITRATE dehydrogenase, RANDOM forest algorithms, MASS spectrometry, TIME-of-flight mass spectrometry
Abstract

Introduction: Biogenic amines play important roles throughout cellular metabolism. This study explores a role of biogenic amines in glioblastoma pathogenesis. Here, we characterize the plasma levels of biogenic amines in glioblastoma patients undergoing standard-of-care treatment. Methods: We examined 138 plasma samples from 36 patients with isocitrate dehydrogenase (IDH) wild-type glioblastoma at multiple stages of treatment. Untargeted gas chromatography–time of flight mass spectrometry (GC-TOF MS) was used to measure metabolite levels. Machine learning approaches were then used to develop a predictive tool based on these datasets. Results: Surgery was associated with increased levels of 12 metabolites and decreased levels of 11 metabolites. Chemoradiation was associated with increased levels of three metabolites and decreased levels of three other metabolites. Ensemble learning models, specifically random forest (RF) and AdaBoost (AB), accurately classified treatment phases with high accuracy (RF: 0.81 ± 0.04, AB: 0.78 ± 0.05). The metabolites sorbitol and N-methylisoleucine were identified as important predictive features and confirmed via SHAP. Conclusion: To our knowledge, this is the first study to describe plasma biogenic amine signatures throughout the treatment of patients with glioblastoma. A larger study is needed to confirm these results with hopes of developing a diagnostic algorithm. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Intraoperative detection of IDH‐mutant glioma using fluorescence lifetime imaging.

Author

Noble Anbunesan, Silvia, Alfonso‐Garcia, Alba, Zhou, Xiangnan, Bec, Julien, Lee, Han Sung, Jin, Lee‐Way, Bloch, Orin, and Marcu, Laura

Abstract

Identifying isocitrate dehydrogenase (IDH)‐mutation and glioma subtype during surgery instead of days later can aid in modifying tumor resection strategies for better survival outcomes. We report intraoperative identification of IDH‐mutant glioma (N = 12 patients) with a clinically compatible fluorescence lifetime imaging (FLIm) device (excitation: 355 nm; emission spectral bands: 390/40 nm, 470/28 nm, 542/50 nm). The fluorescence‐derived parameters were analyzed to study the optical contrast between IDH‐mutant tumors and surrounding brain tissue. IDH‐mutant oligodendrogliomas exhibited shorter lifetimes (3.3 ± 0.1 ns) than IDH‐mutant astrocytomas (4.1 ± 0.1 ns). Both IDH‐mutant glioma subtypes had shorter lifetimes than white matter (4.6 ± 0.4 ns) but had comparable lifetimes to cortex. Lifetimes also increased with malignancy grade within IDH‐mutant oligodendrogliomas (grade 2: 2.96 ± 0.08 ns, grade 3: 3.4 ± 0.3 ns) but not within IDH‐mutant astrocytomas. The current results support the feasibility of FLIm as a surgical adjuvant for identifying IDH‐mutant glioma tissue. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results